Glaukos saw the highest growth of 0.74% in patent filings in April and 1.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.74% and grants by 0.32%. GlobalData’s DataBook provides a comprehensive analysis of Glaukos’s patent filings and grants. Buy the databook here.
Glaukos has been focused on protecting inventions in United States(US) with nine publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 83% filings and 80% grants. The United States(US), Australia(AU), and Canada(CA) patent Office are among the top ten patent offices where Glaukos is filings its patents. Among the top granted patent authorities, Glaukos has 80% of its grants in United States(US) and 20% in Canada(CA).
AbbVie and Roche could be the strongest competitors for Glaukos
In terms of grant share, Glaukos stands in fourth position among its competitors. AbbVie and Roche secured the top positions according to recent patent publication data.
Patents related to cell & gene therapy and healthtech lead Glaukos's portfolio
Glaukos has the highest number of patents in cell & gene therapy followed by, healthtech and smart materials. For cell & gene therapy, nearly 33% of patents were filed and no patents were granted in Q2 2024.
Ophthalmic devices related patents lead Glaukos portfolio followed by drug delivery devices, and presbyopia
Glaukos has highest number of patents in ophthalmic devices followed by drug delivery devices, presbyopia, diabetic macular edema, and keratoconjunctivitis sicca (dry eye). For ophthalmic devices, nearly 33% of patents were filed and 80% of patents were granted in Q2 2024.
For comprehensive analysis of Glaukos's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.